Figure 4.

Outcome of autologous NK cell-based immunotherapy for consolidation treatment of patients with multiple myeloma (MM)

(A) Dynamics of plasma M-component (left, n = 4) and serum-free light chains (right, n = 2) in study subjects in the course of the clinical study. ASCT, autologous stem cell transplant.

(B) IgH variability, diversity, and joining(VDJ) rearrangement analysis of BM samples taken at diagnosis and respective MRD values 2 weeks before the first and 4 weeks after the last infusion of the NK cell product. Percentages of the clonal IgH VDJ sequence (as identified in MM diagnosis samples) out of total IgH VDJ sequences are displayed. Data from 4 of 6 study subjects are shown.

(C and D) (C) PFS and (D) OS of all study subjects (n = 6) during the course of the study calculated from the time of inclusion.